跳到正文
原文
STAT 主站· Elaine Chen·· 11 天前AI 评分55

礼来GLP-1口服药Foundayo在两项晚期研究中改善睡眠呼吸暂停

STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies

AI 导读

两项晚期研究显示,GLP-1 口服药 Foundayo 在睡眠呼吸暂停方面有一定效果,但效果不及注射药物 Zepbound。患者在使用 Foundayo 后,AHI 指数降低了 17.8 事件/小时,而安慰剂组为 4.5 事件/小时。

正文

By Elaine Chen

Nov. 9, 2026

Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.

In a one-year trial of patients who weren’t receiving PAP therapy, a form of ventilation, those on Foundayo saw a reduction of 17.8 “events” per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping. That compares with a reduction of 4.5 events among those on placebo.

Additionally, 28% of treated patients achieved remission or mild disease, compared with 13% in the placebo group, according to data presented Monday at the annual meeting of the American Heart Association and published in JAMA.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com